drugset / Trial / NCT00630695

Prevention of Lymphorrhea by Lanreotide in Axillary Dissection for Breast Cancer

NCT00630695

Phase 3 Completed 148 enrolled University Hospital, Limoges Ipsen · collab
RandomizedParallel-groupDouble-blindPrevention

Summary

Injection the day before surgery of 90 mg of Lanreotide LP sub-cutaneously or placebo. Evaluation of the lymphorrhea in the 2 arms of the study

Timeline

Start
2008-03
Primary completion
2011-06
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Lanreotide Other / unclassified 90 mg Subcutaneous

Indications